J Am Coll Cardiol
Lex Subscribe to read Lex Weight-loss drugs come for Fluffy and Fido Subscribe to Premium for access to our flagship investment column What our readers say "Expert, reliable, considered, actionable opinion" "Brief with no waffle, to the point and has real insight into the corporate world" "Entertaining and often insightful in a way thats different to most newsletters" "It's topical and succinct - a timely and convenient round up of key stories" "Expert, reliable, considered, actionable opinion" "Brief with no waffle, to the point and has real insight into the corporate world" "Entertaining and often insightful in a way thats different to most newsletters" "It's topical and succinct - a timely and convenient round up of key stories" Why the FT

Dihexa and its analogs bind with high affinity to HGF, induce c-Met phosphorylation in the presence of subthreshold levels of HGF, stimulate hippocampal spinogenesis and synaptogenesis equivalent with HGF [81], and promote neurogenesis and cerebro protection (data in preparation for publication)
Development Status The therapy is in late-stage clinical development, currently being evaluated in Phase 3 trials for obesity (weekly subcutaneous administration) with projected completion Expected to be in early 2026
Amycretin's T2D data is from a phase 2 trial with shorter duration